Impact of baseline corticosteroids on survival and steroid androgens in metastatic castration-resistant prostate cancer: Exploratory analysis from COU-AA-301

European Urology

Volumn 67, Issue 5, 2015, Pages 866-873

  Montgomery, Bruce ^a   Kheoh, Thian ^b   Molina, Arturo ^b   Li, Jinhui ^c   Bellmunt, Joaquim ^d   Tran, Namphuong ^b   Loriot, Yohann ^e   Efstathiou, Eleni ^f   Ryan, Charles J ^g   Scher, Howard I ^h   De Bono, Johann S ⁱ  

^a UNIVERSITY OF WASHINGTON   (United States)

^b JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^c JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^d DANA FARBER CANCER INSTITUTE   (United States)

^e INSTITUT GUSTAVE ROUSSY   (France)

^f UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

ⁱ INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Abiraterone; Corticosteroids; Prostate cancer; Survival; Testosterone

Indexed keywords

ABIRATERONE; ALBUMIN; ALKALINE PHOSPHATASE; ANDROGEN; ANDROSTENEDIONE; DEXAMETHASONE; DOCETAXEL; LACTATE DEHYDROGENASE; PLACEBO; PRASTERONE SULFATE; PREDNISOLONE; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE; ANDROSTANE DERIVATIVE; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; CORTICOSTEROID; TAXOID;

ALBUMIN BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANDROGEN BLOOD LEVEL; ANDROSTENEDIONE BLOOD LEVEL; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CIRCULATING TUMOR CELL; EXPLORATORY RESEARCH; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); POST HOC ANALYSIS; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; STATISTICAL SIGNIFICANCE; TESTOSTERONE BLOOD LEVEL; AGED; BLOOD; COMPLICATION; MIDDLE AGED; NEOPLASM METASTASIS; PROGNOSIS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RANDOMIZATION; RISK FACTOR; SURVIVAL; VERY ELDERLY;

ADRENAL CORTEX HORMONES; AGED; AGED, 80 AND OVER; ANDROSTENES; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOMARKERS; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PREDNISONE; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RANDOM ALLOCATION; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL ANALYSIS; TAXOIDS;

EID: 84926177957     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2014.06.042     Document Type: Article

References (24)

1. E.A. Mostaghel, S.R. Plymate, and B. Montgomery Molecular pathways: targeting resistance in the androgen receptor for therapeutic benefit Clin Cancer Res 20 2014 791 798
2. C. Huggins, and C.V. Hodges Studies on prostatic cancer. I. The effect of castration, estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate Cancer Res 1 1941 293 297
3. B. Sahu, M. Laakso, and P. Pihlajamaa FoxA1 specifies unique androgen and glucocorticoid receptor binding events in prostate cancer cells Cancer Res 73 2013 1570 1580
4. R. Tomic, B. Ljungberg, and J.E. Damber Hormonal effects of high dose medroxyprogesterone acetate treatment in males with renal or prostatic adenocarcinoma Scand J Urol Nephrol 22 1988 15 18
5. K. Nishimura, N. Nonomura, and E. Satoh Potential mechanism for the effects of dexamethasone on growth of androgen-independent prostate cancer J Natl Cancer Inst 93 2001 1739 1746
6. I. Tannock, M. Gospodarowicz, W. Meakin, T. Panzarella, L. Stewart, and W. Rider Treatment of metastatic prostatic cancer with low-dose prednisone: evaluation of pain and quality of life as pragmatic indices of response J Clin Oncol 7 1989 590 597
7. A. Yano, Y. Fujii, A. Iwai, S. Kawakami, Y. Kageyama, and K. Kihara Glucocorticoids suppress tumor lymphangiogenesis of prostate cancer cells Clin Cancer Res 12 2006 6012 6017
8. J.A. Storlie, J.C. Buckner, G.A. Wiseman, P.A. Burch, L.C. Hartmann, and R.L. Richardson Prostate specific antigen levels and clinical response to low dose dexamethasone for hormone-refractory metastatic prostate carcinoma Cancer 76 1995 96 100
9. I.F. Tannock, D. Osoba, and M.R. Stockler Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points J Clin Oncol 14 1996 1756 1764
10. R. Venkitaraman, K. Thomas, R.A. Huddart, A. Horwich, D.P. Dearnaley, and C.C. Parker Efficacy of low-dose dexamethasone in castration-refractory prostate cancer BJU Int 101 2008 440 443
11. J.S. de Bono, C.J. Logothetis, and A. Molina Abiraterone and increased survival in metastatic prostate cancer N Engl J Med 364 2011 1995 2005
12. C.J. Ryan, M.R. Smith, and J.S. de Bono Abiraterone in metastatic prostate cancer without previous chemotherapy N Engl J Med 368 2013 138 148
13. C.Y. Chang, P.J. Walther, and D.P. McDonnell Glucocorticoids manifest androgenic activity in a cell line derived from a metastatic prostate cancer Cancer Res 61 2001 8712 8717
14. D. End, A. Molina, M. Todd, and M.L. Meyers Comment on: Interactions of abiraterone, eplerenone, and prednisolone with wild-type and mutant androgen receptor: a rationale for increasing abiraterone exposure or combining with MDV3100 Cancer Res 73 2013 2926
15. M.E. Taplin, G.J. Bubley, and T.D. Shuster Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer N Engl J Med 332 1995 1393 1398
16. V.K. Arora, E. Schenkein, and R. Murali Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade Cell 155 2013 1309 1322
17. H.I. Scher, K. Fizazi, and F. Saad Association of baseline corticosteroid with outcomes in a multivariate analysis of the phase 3 Affirm study of enzalutamide (ENZA), an androgen receptor signaling inhibitor (ARSI) September 28-October 2 2012 Paper presented at: European Society for Medical Oncology meeting Vienna, Austria
18. K. Fizazi, H.I. Scher, and A. Molina Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study Lancet Oncol 13 2012 983 992
19. H.I. Scher, S. Halabi, and I. Tannock Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Grou∗p J Clin Oncol 26 2008 1148 1159
20. C.J. Ryan, A. Molina, and J. Li Serum androgens as prognostic biomarkers in castration-resistant prostate cancer: results from an analysis of a randomized phase III trial J Clin Oncol 31 2013 2791 2798
21. K.N. Chi, T. Kheoh, and C.J. Ryan A prognostic model for predicting overall survival (OS) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone acetate (AA) after docetaxel [abstract 5013] J Clin Oncol 31 2013 (Suppl)
22. P.F. Mulders, A. Molina, and M. Marberger Efficacy and safety of abiraterone acetate in an elderly patient subgroup (aged 75 and older) with metastatic castration-resistant prostate cancer after docetaxel-based chemotherapy Eur Urol 65 2014 875 883
23. C.J. Ryan, W. Peng, and T. Kheoh Androgen dynamics and serum PSA in patients treated with abiraterone acetate Prostate Cancer Prostatic Dis 17 2014 192 198
24. S.D. Fossa, P.H. Slee, and M. Brausi Flutamide versus prednisone in patients with prostate cancer symptomatically progressing after androgen-ablative therapy: a phase III study of the European organization for research and treatment of cancer genitourinary group J Clin Oncol 19 2001 62 71